🔗 Share this article WHO Raises Alert Over Severe Lack of Weight-Loss Jabs Under 10% of individuals who could benefit from obesity jabs such as Wegovy can access them, caution the global health agency as it issues its initial advice on the drugs. With over a billion people worldwide currently obese, it is urging increased and just access to GLP-1 medication. Per estimates, over two billion will be obese by 2030 without intervention. "Our latest guidelines acknowledges that obesity is a long-term condition that can be addressed with comprehensive and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and logistical bottlenecks are key obstacles to universal availability to the injections that can aid individuals in losing significant weight, notes the agency. Skinny Jab Shortage Even in the present best projected outlook, the production of these medications could only cover approximately 100 million people – under 10% of those who need them, as stated by the health organization. The guideline encourages countries and companies to widen availability, by measures including licensing agreements. A patent on semaglutide – the core component of a leading brand – is set to lapse in several countries in 2026. How Weight-Loss Jabs Operate The injections replicate a biological compound to delay gastric emptying, curb appetite and enhance feelings of fullness so individuals consume fewer calories. People typically begin shedding pounds after several weeks of commencing the once-weekly jabs. Evidence indicates users may see weight return a year later of halting the medication, because their typical food cravings return. Being carrying excess weight increases your likelihood for experiencing health problems, such as diabetes, cardiovascular issues, stroke, and some malignancies. Excess weight affects individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
Under 10% of individuals who could benefit from obesity jabs such as Wegovy can access them, caution the global health agency as it issues its initial advice on the drugs. With over a billion people worldwide currently obese, it is urging increased and just access to GLP-1 medication. Per estimates, over two billion will be obese by 2030 without intervention. "Our latest guidelines acknowledges that obesity is a long-term condition that can be addressed with comprehensive and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and logistical bottlenecks are key obstacles to universal availability to the injections that can aid individuals in losing significant weight, notes the agency. Skinny Jab Shortage Even in the present best projected outlook, the production of these medications could only cover approximately 100 million people – under 10% of those who need them, as stated by the health organization. The guideline encourages countries and companies to widen availability, by measures including licensing agreements. A patent on semaglutide – the core component of a leading brand – is set to lapse in several countries in 2026. How Weight-Loss Jabs Operate The injections replicate a biological compound to delay gastric emptying, curb appetite and enhance feelings of fullness so individuals consume fewer calories. People typically begin shedding pounds after several weeks of commencing the once-weekly jabs. Evidence indicates users may see weight return a year later of halting the medication, because their typical food cravings return. Being carrying excess weight increases your likelihood for experiencing health problems, such as diabetes, cardiovascular issues, stroke, and some malignancies. Excess weight affects individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.